Engineered amylase variants
The present invention provides engineered amylase polypeptides and compositions thereof. The engineered amylase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH<7) conditions. The invention also relates to the use of the compositions comprising the engineered amylase polypeptides for therapeutic and/or nutritional purposes. The present invention also provides polynucleotides encoding the engineered amylase polypeptides, as well as methods for making the engineered polynucleotides and amylase polypeptides.
1. A recombinant amylase comprising a polypeptide sequence comprising at least 90% sequence identity to SEQ ID NO: 1728, wherein the polypeptide sequence comprises at least a substitution 272G/K/P/R/S, 394E/G/N/R/S, or 91H, or any combinations thereof, wherein the amino acid positions are relative to SEQ ID NO: 2.
2. The recombinant amylase of claim 1 , wherein the polypeptide sequence comprises SEQ ID NO: 156, 174, 276, 308, 422, 456, 546, 632, 664, 780, 810, 1104, 1122, 1224, 1256, 1370, 1404, 1494, 1580, 1612, 1728, or 1758.
3. The recombinant amylase of claim 1 , wherein said recombinant amylase exhibits at least one improved property selected from: i) enhanced catalytic activity; ii) increased tolerance to acidic pH conditions; iii) increased tolerance to at least one protease; iv) increased tolerance to at least one bile salt; v) increased thermotolerance; or a combination of any of i), ii), iii), iv), and v), as compared to a reference amylase having the sequence of SEQ ID NO: 2 or 18.
4. A composition comprising at least one recombinant amylase of claim 1 .
5. A pharmaceutical composition comprising the recombinant amylase of claim 1 , and a pharmaceutically acceptable carrier or excipient.
6. The recombinant amylase of claim 1 , comprising a polypeptide sequence comprising at least 91% sequence identity to SEQ ID NO: 1728.
7. The recombinant amylase of claim 1 , comprising a polypeptide sequence comprising at least 95% sequence identity to SEQ ID NO: 1728.
8. The recombinant amylase of claim 1 , comprising a polypeptide sequence comprising at least 99% sequence identity to SEQ ID NO: 1728.
9. The recombinant amylase of claim 1 , wherein the polypeptide sequence comprises at least the substitution 272G, 272K, 272P, 272R, or 272S.
10. The recombinant amylase of claim 1 , wherein the polypeptide sequence comprises at least the substitution 394E, 394G, 394N, 394R, or 394S.
11. The recombinant amylase of claim 1 , wherein the polypeptide sequence comprises at least the substitution 91H.
12. The recombinant amylase of claim 1 , wherein the polypeptide sequence comprises at least the substitution 272G, 394G, or 91H, or any combinations thereof.
13. The recombinant amylase of claim 1 , comprising a polypeptide sequence comprising at least 92% sequence identity to SEQ ID NO: 1728.
14. The recombinant amylase of claim 1 , comprising a polypeptide sequence comprising at least 93% sequence identity to SEQ ID NO: 1728.
15. The recombinant amylase of claim 1 , comprising a polypeptide sequence comprising at least 94% sequence identity to SEQ ID NO: 1728.
16. The recombinant amylase of claim 1 , comprising a polypeptide sequence comprising at least 96% sequence identity to SEQ ID NO: 1728.
17. The recombinant amylase of claim 1 , comprising a polypeptide sequence comprising at least 97% sequence identity to SEQ ID NO: 1728.
18. The recombinant amylase of claim 1 , comprising a polypeptide sequence comprising at least 98% sequence identity to SEQ ID NO: 1728.